These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Harmonization of testing drugs for bioequivalence: problems and possible solutions]. Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051 [TBL] [Abstract][Full Text] [Related]
4. Bayesian modeling of multivariate average bioequivalence. Ghosh P; Gönen M Stat Med; 2008 Jun; 27(13):2402-19. PubMed ID: 18095275 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs. Karalis V; Symillides M; Macheras P Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039 [TBL] [Abstract][Full Text] [Related]
6. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles. Rajaram L; Roy SK; Skerjanec A Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918 [TBL] [Abstract][Full Text] [Related]
7. [Review and use of decision rules for bioequivalence trials]. Nicolas P; Tod M; Petitjean O Therapie; 1993; 48(1):15-22. PubMed ID: 8356540 [TBL] [Abstract][Full Text] [Related]
8. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations. Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107 [TBL] [Abstract][Full Text] [Related]
9. Assessing individual bioequivalence using the structural equation model. Carrasco JL; Jover L Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408 [TBL] [Abstract][Full Text] [Related]
10. [Assessment of bioequivalence]. Aoyagi N Eisei Shikenjo Hokoku; 1996; (114):141-2. PubMed ID: 9037886 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of bioequivalence trials. From analysis to statistic trials]. Houin G Therapie; 1993; 48(4):289-95. PubMed ID: 8128417 [No Abstract] [Full Text] [Related]
12. [Bioequivalence of generic drugs]. Schwabe U Internist (Berl); 1988 Mar; 29(3):147-59. PubMed ID: 3288573 [No Abstract] [Full Text] [Related]
13. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Schall R Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849 [TBL] [Abstract][Full Text] [Related]
14. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use]. Zapater P; Horga JF Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753 [TBL] [Abstract][Full Text] [Related]
15. Robust and bootstrap testing procedures for bioequivalence. Shen CF; Iglewicz B J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585 [TBL] [Abstract][Full Text] [Related]
16. [Bioequivalence and therapeutic exchange of pharmaceutical specialties: application to cyclosporin in renal transplantation]. Pérez Ruixo JJ; Porta B; Jiménez Torres NV Nefrologia; 2003; 23(1):71-80. PubMed ID: 12708379 [TBL] [Abstract][Full Text] [Related]
17. Levothyroxine dosage and the limitations of current bioequivalence standards. Hennessey JV Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756 [No Abstract] [Full Text] [Related]
18. A method for the evaluation of individual bioequivalence. Endrenyi L Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334 [TBL] [Abstract][Full Text] [Related]
19. The application of new bioavailability parameters in the bioequivalence testing of antimicrobial agents. Wessels JC; Koeleman HA; Steyn HS; Ellis SM Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):542-6. PubMed ID: 8294166 [TBL] [Abstract][Full Text] [Related]
20. Tests for individual and population bioequivalence based on generalized p-values. McNally RJ; Iyer H; Mathew T Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]